Charles Schwab Investment Management Inc. Has $2.09 Million Stock Position in Accolade, Inc. (NASDAQ:ACCD)

Charles Schwab Investment Management Inc. grew its holdings in shares of Accolade, Inc. (NASDAQ:ACCD) by 7.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 611,731 shares of the company’s stock after purchasing an additional 42,530 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Accolade were worth $2,092,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Intech Investment Management LLC purchased a new stake in shares of Accolade in the third quarter valued at about $96,000. Point72 Asia Singapore Pte. Ltd. boosted its holdings in Accolade by 1,144.1% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company’s stock valued at $81,000 after purchasing an additional 19,232 shares during the period. Clearline Capital LP raised its position in shares of Accolade by 85.3% in the third quarter. Clearline Capital LP now owns 1,539,578 shares of the company’s stock worth $5,927,000 after buying an additional 708,794 shares in the last quarter. Centiva Capital LP raised its holdings in shares of Accolade by 5.8% in the 3rd quarter. Centiva Capital LP now owns 59,660 shares of the company’s stock valued at $230,000 after acquiring an additional 3,264 shares in the last quarter. Finally, Mission Creek Capital Partners Inc. bought a new stake in shares of Accolade during the 3rd quarter valued at about $38,000. 84.99% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ACCD shares. Stifel Nicolaus reissued a “hold” rating and issued a $7.03 price target (down previously from $8.00) on shares of Accolade in a research note on Thursday, January 9th. Raymond James reaffirmed a “market perform” rating on shares of Accolade in a research note on Thursday, January 9th. Needham & Company LLC reiterated a “hold” rating on shares of Accolade in a research report on Wednesday, January 8th. William Blair downgraded Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Finally, Piper Sandler cut shares of Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Thirteen equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, Accolade currently has a consensus rating of “Hold” and a consensus target price of $6.51.

Accolade Price Performance

Shares of Accolade stock opened at $6.99 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.63 and a quick ratio of 2.63. Accolade, Inc. has a one year low of $3.08 and a one year high of $10.45. The business’s 50 day simple moving average is $6.94 and its two-hundred day simple moving average is $4.95. The stock has a market capitalization of $573.13 million, a P/E ratio of -3.11 and a beta of 2.18.

Accolade (NASDAQ:ACCD) last issued its earnings results on Friday, January 10th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. Analysts forecast that Accolade, Inc. will post -1.2 EPS for the current year.

Accolade Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.